Delia C. Yu
De La Salle Health Sciences Institute Congressional Road
Cavite, Philippines
Cavite, Philippines
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 12, 2024
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
Journal: The Journal of infectious diseases
Published: June 01, 2023
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Global health
Published: February 22, 2023
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study.
Journal: Expert review of vaccines
Published: February 28, 2022
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 27, 2021
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
Journal: The Journal of infectious diseases
Published: October 08, 2020
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: February 13, 2020
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: January 27, 2020
Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Journal: The Lancet. Infectious diseases
Published: September 18, 2017
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
Journal: PLoS neglected tropical diseases
Published: May 04, 2017
Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Journal: The Lancet. Infectious diseases
Published: November 08, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026